The capital’s pharmaceutical industry has received a new impetus for the development of biotechnologies. Resident of the “Technopolis Moscow” special economic zone (SEZ), the company Amedart, is launching a large-scale project for the production of pharmaceutical substances and finished medicines. Total investments in the creation of the new production line will exceed 800 million rubles.
City Support and Concessional Financing
The implementation of such a large project became possible thanks to the financial support of the Moscow Government. The company took advantage of the program of the Moscow Fund for Industry and Entrepreneurship Support (MFPIPS), which allows compensating part of the costs of servicing an investment loan.
This mechanism reduces the loan rate for the enterprise to half of the Central Bank’s key rate, making borrowed funds accessible for high-tech businesses. According to the press service of the city’s Department of Investment and Industrial Policy (DIIP), Maxim Liksutov, Deputy Mayor of Moscow for Transport and Industry, spoke about the significance of this step:
“On the instructions of Moscow Mayor Sergey Sobyanin, the city pays special attention to the pharmaceutical industry. Effective mechanisms are in place for enterprises that promote the development of new areas and the expansion of the range of manufactured products. Thus, with the help of the interest rate compensation program from the Moscow Fund for Industry and Entrepreneurship Support, a capital company will launch the production of biotechnological pharmaceutical substances and medicines on the territory of the Technopolis Moscow special economic zone.”
— Maxim Liksutov, Deputy Mayor of Moscow for Transport and Industry
What Will Be Produced?
The new facilities in the Technopolis Moscow SEZ are planned to produce a wide range of vital medicines, including:
- Antitumor drugs;
- Antiretroviral agents (for HIV therapy);
- Antidiabetic drugs;
- Antibiotics.
Special emphasis in the project is placed on the production of biotechnological substances — the active raw material for drugs. This is a critically important area for ensuring real import substitution and the country’s medical sovereignty. In addition, the launch of the new site will create more than 100 high-tech jobs in the city.
Partnership with Business and Banks
Sberbank provided credit funds for the development of production. German Barg, Chairman of the Moscow Bank of Sberbank, noted that today all conditions have been created in the capital to scale complex science-intensive projects “from idea to mass production.”
Andrei Kolokoltsov, CEO of Amedart, in turn, emphasized: systematic city support gives the enterprise the opportunity not just to mechanically expand capacities, but also to actively introduce advanced technologies into the production process itself.
Context: Growth of Capital Pharma
The preferential lending program through MFPIPS, which the company used, has been successfully operating for several years. Anatoly Garbuzov, Minister of the Moscow Government and Head of the Department of Investment and Industrial Policy, provided statistics on its demand:
“Since 2022, under this program, the fund has helped more than 170 companies attract over 300 billion rubles. Among them are manufacturers of medicines, food products, auto components, and representatives of other industries. Thanks to such support, they can modernize production facilities, implement innovative technologies, and create new jobs.”
— Anatoly Garbuzov, Minister of the Moscow Government, Head of DIIP
The effectiveness of these measures is confirmed by official statistics: earlier, Moscow Mayor Sergey Sobyanin reported that in the first 11 months of 2025, the volume of drug production in the capital increased by 11.8% compared to the same period last year.
Subscribe to the PHARMPROM Newsletter
Pharmaceutical industry news, event announcements, and expert materials.
